(Q37798898)

23 August 2017

Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues (English)

1 reference

23 August 2017

1 reference

peripheral neuropathy

1 reference

Philip Van Damme

8

0 references

Athanasios Dimopoulos

object named as

Meletios A Dimopoulos

series ordinal

3

0 references

Pieter Sonneveld

series ordinal

10

object named as

Pieter Sonneveld

1 reference

23 August 2017

4

Thierry Facon

1 reference

23 August 2017

7

Antonio Palumbo

1 reference

23 August 2017

6

Heinz Ludwig

1 reference

23 August 2017

2

Joan Bladé

1 reference

23 August 2017

1

Michel Delforge

1 reference

23 August 2017

Martin Kropff

5

1 reference

PubMed ID

20932799

23 August 2017

Jesús F San-Miguel

series ordinal

9

1 reference

23 August 2017

1 November 2010

1 reference

Lancet Oncology Commission

23 August 2017

1 reference

23 August 2017

11

1 reference

23 August 2017

11

1 reference

23 August 2017

1086-1095

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

23 August 2017

1 reference

7 January 2021

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

7 January 2021

A phase 2 study of bortezomib in relapsed, refractory myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

7 January 2021

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

7 January 2021

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

7 January 2021

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

7 January 2021

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

7 January 2021

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

7 January 2021

Peripheral nervous system involvement in patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

7 January 2021

Chemotherapy-induced neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

7 January 2021

Thalidomide neuropathy: a clinical electrophysiological, and histological follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

7 January 2021

Quantitative Sensory Findings in Patients With Bortezomib-Induced Pain

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

7 January 2021

Thalidomide-induced neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

7 January 2021

Peripheral neuropathy associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

7 January 2021

Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

7 January 2021

Thalidomide-induced bradycardia and its management.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

7 January 2021

Thalidomide induced impotence in male hematology patients: a common but ignored complication?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

7 January 2021

Neuropathy after intake of thalidomide (distaval)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

7 January 2021

Thalidomide: tragic past and promising future

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

7 January 2021

Thalidomide and dexamethasone combination for refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

7 January 2021

A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

7 January 2021

Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

7 January 2021

Thalidomide maintenance following high-dose therapy in multiple myeloma: a UK myeloma forum phase 2 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

7 January 2021

A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

7 January 2021

Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

7 January 2021

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

7 January 2021

Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

7 January 2021

Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

7 January 2021

Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

7 January 2021

Thalidomide and hematopoietic-cell transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

7 January 2021

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

7 January 2021

Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

7 January 2021

Neuropathy in multiple myeloma treated with thalidomide: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

7 January 2021

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

7 January 2021

Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

7 January 2021

Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

7 January 2021

Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

7 January 2021

Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

7 January 2021

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

7 January 2021

Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

7 January 2021

An observational, retrospective analysis of retreatment with bortezomib for multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

7 January 2021

Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

7 January 2021

Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

7 January 2021

Review of peripheral neuropathy in plasma cell disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

7 January 2021

Thalidomide-induced neuropathy and genetic differences in drug metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

7 January 2021

Fetal nerve cell degeneration produced by thalidomide in rabbits.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

7 January 2021

Thalidomide neuropathy: clinical, electrophysiological and neuroradiological features

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

7 January 2021

Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

7 January 2021

Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

7 January 2021

Activation of nuclear factor-kappaB via endogenous tumor necrosis factor alpha regulates survival of axotomized adult sensory neurons.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

7 January 2021

Thalidomide has activity in treating complex regional pain syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

7 January 2021

Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

7 January 2021

Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: a possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

7 January 2021

Thalidomide sensory neurotoxicity: a clinical and neurophysiologic study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

7 January 2021

Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

7 January 2021

Thalidomide and sensory neurotoxicity: a neurophysiological study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

7 January 2021

The Functional Assessment of Cancer Therapy scale: development and validation of the general measure

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

7 January 2021

Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

7 January 2021

Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

7 January 2021

Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

7 January 2021

Ascorbic acid inhibits antitumor activity of bortezomib in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

7 January 2021

From bench to bedside: a case of rapid reversal of bortezomib-induced neuropathic pain by the TRPM8 activator, menthol

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970068-1

7 January 2021

10.1016/S1470-2045(10)70068-1

Identifiers

DOI

1 reference

23 August 2017

1 reference

PubMed ID

20932799